Respiratorius Project Portfolio
VAL001 has shown clearly promising experimental and clinical data against diseases such as diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin’s lymphoma.
The Company has successfully completed a phase I/IIa study that was conducted at Skåne University Hospital in Lund, Uppsala University Hospital, and Norrland University Hospital in Umeå.
Board of Directors and CEO
A competent team with extensive experience in both business development and commercialization of research findings as well as strong scientific background in relevant areas complemented with knowledge in clinical development and design of clinical trials.
Karin Wehlin
Chairman of the Board
Karin has extensive experience in corporate governance, corporate strategy, and financial management. Within healthcare, she is the co-founder and has served as the Chairman of the Board for 10 years of EQL Pharma AB and been holding the position as CEO at Respiratorius AB. She has further significant experience in the food industry value chain through her decade long experience as the CEO of Bomill AB, as the current Chair of the Board at Innoscentia AB, and as the CEO of LU Food Science. Her financial management roles have included corporate finance positions at Sedermera Corporate Finance Advisory AB and CFO of Nordic Drugs AB. She has also been on the BoD of Danske Bank AB.
Respiratorius strongly believes that Karin’s expertise in financial management, corporate governance and corporate strategy will be complementary to the BoD.
Johan Drott
CEO
Johan has an extensive experience in senior positions in medical device and pharmaceutical companies with a focus on research, business development and commercialization of research findings.
Kristina Drott
Board member
Kristina is associate professor at the Faculty of Medicine, Lund University and senior consultant of lymphoma oncology at Skåne University Hospital.
Mia Lundblad
Board member
Mia Lundblad, holds a Master of Pharmacy degree from Uppsala University and a PhD in Clinical Pharmacology from Karolinska Institutet. Mia Lundblad has extensive experience in pharmaceutical research and development, project management, and business development from leading positions at Novo Nordisk, Ferring Pharmaceuticals, and Respiratorius. Currently, Mia Lundblad is the Clinical Pharmacology Scientific Director at Novo Nordisk and has previously served as CEO at Arcede Pharma.
